Sulfamerazine

Summary

Sulfamerazine (CHEMBL438) is an approved small-molecule antiinfective agent (ATC D06BA06); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D06BA06 (+1 more)
• Indications: 1 condition
• Chemistry: 264.31 Da · C11H12N4O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL438
Name	Sulfamerazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5325
ChEBI	CHEBI:102130
ATC	D06BA06, J01ED07
Molecular formula	C11H12N4O2S
Molecular weight	264.31
InChIKey	QPPBRPIAZZHUNT-UHFFFAOYSA-N

SMILES: CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N

IUPAC name: 4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide

ChEBI definition: A sulfonamide consisting of pyrimidine with a methyl substituent at the 4-position and a 4-aminobenzenesulfonamido group at the 2-position.

Pharmacological roles (ChEBI): antiinfective agent, drug allergen.

Also known as: Mesulfa, Methypyrimal, NSC-27259, Sulfamerazina, Sulfamerazine, Sulfamerazine component of lantrisul, Sulfamerazine component of neotrizine, Sulfamerazine component of sulfaloid, Sulfamerazine component of sulfose, Sulfamerazine component of terfonyl, Sulphamerazine, Sulfamethyldiazine

Parent form; salt/anhydrous children: CHEMBL2107260

Patent coverage: 1,635 distinct patent families (5,057 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,054 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Microtubule-associated protein tau, Beta-lactamase, Cytochrome P450 2C9.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C9	8.3	Potency	5	nM	CHEMBL_ACT_5029478

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).